January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” 8 citations
,
January 2023 in “Journal of Research in Pharmacy” Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
20 citations
,
October 2003 in “The Journal of Dermatology” DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.
8 citations
,
March 2018 in “Journal of Drug Delivery Science and Technology” Itraconazole-loaded nanoparticles are more effective and less toxic for treating fungal infections than conventional oral itraconazole.
20 citations
,
December 2011 in “Journal of inherited metabolic disease” Valproic acid treatment increases a specific acid in urine by blocking an enzyme, possibly causing skin rash and hair loss.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
March 2023 in “Oxford University Press eBooks” 11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
2 citations
,
January 2012 in “Hair therapy & transplantation” DDAIP-HCl significantly increases minoxidil absorption into the skin.
17 citations
,
August 2019 in “JAMA Facial Plastic Surgery” Some men lost hair after deoxycholic acid treatment for neck fat, but most saw improvement or resolution.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
8 citations
,
January 2021 in “Pharmaceutics” Nanoporous silica entrapped lipid-drug complexes significantly improve the solubility and absorption of drugs that don't dissolve well in water.
February 2023 in “Reactions Weekly” 64 citations
,
May 2000 in “International Journal of Dermatology” Thalidomide improved lupus symptoms but caused nerve damage in some patients.
January 2026 in “Journal of Ethnopharmacology” Cedrol promotes hair growth better than baricitinib by regulating immune cells.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
October 2025 in “Dermatology and Therapy”